Releases Details
Grant Of Options
Released : January 24, 2020 16:31
MaxCyte, Inc.
("MaxCyte" or the "Company")
Grant of Options
|
Option Grants to PDMRs |
|
|
Doerfler, Doug |
390,200 |
|
Holtz, Ron |
177,600 |
|
Thompson, J. Stark |
26,900 |
|
Mandell, Art |
26,900 |
|
Erck, Stan |
26,900 |
|
Brooke, Will |
26,900 |
|
Johnston, John |
26,900 |
|
Douglas, Richard |
26,900 |
|
Total |
729,200 |
Options Grants to PDMRs vest ratably on a monthly basis over 48 months, have an exercise period of 10 years from date of grant, at which time they will expire, and have an exercise price equal to the closing price of MaxCyte's stock on 20 January 2020, of
The information set out below is provided in accordance with the requirements of Regulation 19(3) of the EU Market Abuse Regulation No 596/2014:
|
1 |
Details of the person discharging managerial responsibilities / person closely associated |
|
|
a) |
Names |
Doerfler, Doug Holtz, Ron Thompson, J. Stark Mandell, Art Erck, Stan Brooke, Will Johnston, John Douglas, Richard |
|
2 |
Reason for the notification |
|
|
a) |
Position/status
|
Doerfler, Doug - CEO and Director Holtz, Ron - CFO and Director Thompson, J. Stark - Non-executive Chairman Mandell, Art - Non-executive Director Erck, Stan - Non-executive Director Brooke, Will - Non-executive Director Johnston, John - Non-executive Director Douglas, Richard - Non-executive Director |
|
b) |
Initial notification /Amendment |
Initial Notification |
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|
|
a) |
Name |
MaxCyte, Inc. |
|
b) |
LEI |
54930053YHXULRFCU991 |
|
4
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|
|
a)
|
Description of the financial instrument, type of instrument |
Grant of Options over Shares of Common Stock |
|
b) |
Identification code |
US57777K1060 |
|
c) |
Nature of the transactions |
Grant of Options to PDMRs |
|
d)
|
Price(s) and volume(s) |
Doerfler, Doug - 390,200 at an exercise price of Holtz, Ron - 177,600 at an exercise price of Thompson, J. Stark - 26,900 at an exercise price of Mandell, Art - 26,900 at an exercise price of Erck, Stan - 26,900 at an exercise price of Brooke, Will - 26,900 at an exercise price of Johnston, John - 26,900 at an exercise price of Douglas, Richard - 26,900 at an exercise price of |
|
d)
|
Aggregated information - Aggregated volume - Price |
n/a |
|
e)
|
Date of the transactions |
20 January 2020 |
|
f) |
Place of the transaction |
Outside a trading venue |
About MaxCyte
MaxCyte is a clinical-stage global cell-based therapies and life sciences company applying its proprietary cell engineering platform to deliver the advances of cell-based medicine to patients with high unmet medical needs. Through its life sciences business, MaxCyte leverages its Flow Electroporation® Technology to enable its biopharmaceutical partners to advance the development of innovative medicines, particularly in cell therapy. MaxCyte has placed its technology worldwide, including with all of the top ten global biopharmaceutical companies. The Company now has more than 100 partnered programme licenses in cell therapy with more than 70 licensed for clinical use. The Company has now signed eight clinical/commercial licenses with leading cell therapy developers and the potential pre-commercial milestones from these relationships now exceeds
For further information, please contact:
|
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the
